Global Peripheral Arterial Disease (PAD) Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Peripheral Arterial Disease (PAD) treatment during 2019. Clinical development activities are being undertaken by more than 35 companies including 480 Biomedical Inc, Alucent Medical Inc, Anaeropharma Science Inc, AnGes MG Inc, AngioSoma Inc and others.
A Significant contribution to the Peripheral Arterial Disease (PAD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Peripheral Arterial Disease (PAD) pipeline included 35 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Peripheral Arterial Disease (PAD) condition and increased access to investments is encouraging growth of Peripheral Arterial Disease (PAD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Peripheral Arterial Disease (PAD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Peripheral Arterial Disease (PAD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Peripheral Arterial Disease (PAD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Peripheral Arterial Disease (PAD). Further, orphan drug status, fast track designation, grants awarded and other special status for Peripheral Arterial Disease (PAD) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Peripheral Arterial Disease (PAD) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Peripheral Arterial Disease (PAD) Pipeline candidates-
A Significant contribution to the Peripheral Arterial Disease (PAD) pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Peripheral Arterial Disease (PAD) pipeline included 35 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Peripheral Arterial Disease (PAD) condition and increased access to investments is encouraging growth of Peripheral Arterial Disease (PAD) drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Peripheral Arterial Disease (PAD) drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Peripheral Arterial Disease (PAD) therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Peripheral Arterial Disease (PAD) pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Peripheral Arterial Disease (PAD). Further, orphan drug status, fast track designation, grants awarded and other special status for Peripheral Arterial Disease (PAD) pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Peripheral Arterial Disease (PAD) pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Peripheral Arterial Disease (PAD) Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Peripheral Arterial Disease (PAD) drugs
- Late phase: Phase 3 and in-approval Peripheral Arterial Disease (PAD) drugs
- Company overview
- Snapshot
- Peripheral Arterial Disease (PAD) therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Peripheral Arterial Disease (PAD)- Disease Overview
2.2 Peripheral Arterial Disease (PAD)- Pipeline Snapshot
2.3 Peripheral Arterial Disease (PAD)- Pipeline Drugs by Phase
2.4 Peripheral Arterial Disease (PAD)- Pipeline Drugs by Company
2.5 Peripheral Arterial Disease (PAD)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 480 Biomedical Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.2 Alucent Medical Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.3 Anaeropharma Science Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.4 AnGes MG Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.5 AngioSoma Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.6 Apceth Biopharma GmbH Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.7 Athera Biotechnologies AB Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.8 Athersys Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.9 Bayer AG Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.10 Betagenon AB Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.11 BiogenCell Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.12 CardioVascular BioTherapeutics Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.13 Celularity Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.14 Exodos Life Sciences LP Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.15 Foresee Pharmaceuticals Co Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.16 G. Pohl-Boskamp GmbH & Co. KG Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.17 Hemostemix Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.18 ID Pharma Co Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.19 Juventas Therapeutics Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.20 LipimetiX Development Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.21 MultiGene Vascular Systems (MGVS) Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.22 Nangiotx Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.23 Novartis AG Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.24 Nuo Therapeutics Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.25 Pluristem Therapeutics Inc. Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.26 Proteon Therapeutics Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.27 Resverlogix Corporation Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.28 Reven Pharmaceuticals Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.29 RHEACELL GmbH & Co. KG Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.30 SK Chemicals Co.,Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.31 Stemedica Cell Technologies Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.32 Symic Biomedical Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.33 VESSL Therapeutics Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.34 ViroMed Co Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.35 Yuyu Pharma Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Peripheral Arterial Disease (PAD)- Phase 1 Drug Details
4.2 Peripheral Arterial Disease (PAD)- Phase 1 Drug Overview
4.3 Peripheral Arterial Disease (PAD)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Peripheral Arterial Disease (PAD)- Phase 2 Drug Details
5.2 Peripheral Arterial Disease (PAD)- Phase 2 Drug Overview
5.3 Peripheral Arterial Disease (PAD)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Peripheral Arterial Disease (PAD)- Phase 3 Drug Details
6.2 Peripheral Arterial Disease (PAD)- Phase 3 Drug Overview
6.3 Peripheral Arterial Disease (PAD)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Peripheral Arterial Disease (PAD)- Pre-clinical Phase Drug Details
7.2 Peripheral Arterial Disease (PAD)- Pre-clinical Phase Drug Overview
7.3 Peripheral Arterial Disease (PAD)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Peripheral Arterial Disease (PAD)- Disease Overview
2.2 Peripheral Arterial Disease (PAD)- Pipeline Snapshot
2.3 Peripheral Arterial Disease (PAD)- Pipeline Drugs by Phase
2.4 Peripheral Arterial Disease (PAD)- Pipeline Drugs by Company
2.5 Peripheral Arterial Disease (PAD)- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 480 Biomedical Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.2 Alucent Medical Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.3 Anaeropharma Science Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.4 AnGes MG Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.5 AngioSoma Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.6 Apceth Biopharma GmbH Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.7 Athera Biotechnologies AB Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.8 Athersys Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.9 Bayer AG Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.10 Betagenon AB Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.11 BiogenCell Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.12 CardioVascular BioTherapeutics Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.13 Celularity Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.14 Exodos Life Sciences LP Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.15 Foresee Pharmaceuticals Co Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.16 G. Pohl-Boskamp GmbH & Co. KG Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.17 Hemostemix Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.18 ID Pharma Co Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.19 Juventas Therapeutics Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.20 LipimetiX Development Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.21 MultiGene Vascular Systems (MGVS) Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.22 Nangiotx Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.23 Novartis AG Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.24 Nuo Therapeutics Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.25 Pluristem Therapeutics Inc. Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.26 Proteon Therapeutics Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.27 Resverlogix Corporation Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.28 Reven Pharmaceuticals Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.29 RHEACELL GmbH & Co. KG Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.30 SK Chemicals Co.,Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.31 Stemedica Cell Technologies Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.32 Symic Biomedical Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.33 VESSL Therapeutics Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.34 ViroMed Co Ltd Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
3.35 Yuyu Pharma Inc Peripheral Arterial Disease (PAD) Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Peripheral Arterial Disease (PAD)- Phase 1 Drug Details
4.2 Peripheral Arterial Disease (PAD)- Phase 1 Drug Overview
4.3 Peripheral Arterial Disease (PAD)- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Peripheral Arterial Disease (PAD)- Phase 2 Drug Details
5.2 Peripheral Arterial Disease (PAD)- Phase 2 Drug Overview
5.3 Peripheral Arterial Disease (PAD)- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Peripheral Arterial Disease (PAD)- Phase 3 Drug Details
6.2 Peripheral Arterial Disease (PAD)- Phase 3 Drug Overview
6.3 Peripheral Arterial Disease (PAD)- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Peripheral Arterial Disease (PAD)- Pre-clinical Phase Drug Details
7.2 Peripheral Arterial Disease (PAD)- Pre-clinical Phase Drug Overview
7.3 Peripheral Arterial Disease (PAD)- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
